- Home
- NNVC vs SYBX Comparison
NNVC vs SYBX Comparison
Compare NNVC & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNVC
- SYBX
- Stock Information
- Founded
- NNVC 2005
- SYBX N/A
- Country
- NNVC United States
- SYBX United States
- Employees
- NNVC N/A
- SYBX N/A
- Industry
- NNVC Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- NNVC Health Care
- SYBX Health Care
- Exchange
- NNVC Nasdaq
- SYBX Nasdaq
- Market Cap
- NNVC 23.1M
- SYBX 20.0M
- IPO Year
- NNVC N/A
- SYBX N/A
- Fundamental
- Price
- NNVC $1.53
- SYBX $1.81
- Analyst Decision
- NNVC
- SYBX
- Analyst Count
- NNVC 0
- SYBX 0
- Target Price
- NNVC N/A
- SYBX N/A
- AVG Volume (30 Days)
- NNVC 223.4K
- SYBX 36.4K
- Earning Date
- NNVC 11-13-2025
- SYBX 11-11-2025
- Dividend Yield
- NNVC N/A
- SYBX N/A
- EPS Growth
- NNVC N/A
- SYBX N/A
- EPS
- NNVC N/A
- SYBX N/A
- Revenue
- NNVC N/A
- SYBX N/A
- Revenue This Year
- NNVC N/A
- SYBX N/A
- Revenue Next Year
- NNVC $133.33
- SYBX N/A
- P/E Ratio
- NNVC N/A
- SYBX N/A
- Revenue Growth
- NNVC N/A
- SYBX N/A
- 52 Week Low
- NNVC $0.94
- SYBX $0.90
- 52 Week High
- NNVC $1.92
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- NNVC 56.07
- SYBX 59.32
- Support Level
- NNVC $1.40
- SYBX $1.64
- Resistance Level
- NNVC $1.63
- SYBX $1.80
- Average True Range (ATR)
- NNVC 0.09
- SYBX 0.09
- MACD
- NNVC 0.02
- SYBX 0.00
- Stochastic Oscillator
- NNVC 67.65
- SYBX 78.95
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.